Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC. (NVAX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
1.36(c) 1.4(c) 1.39(c) 1.42(c) 1.43(c) Last
2 570 996 3 417 116 1 696 728 2 197 195 2 176 505 Volume
-0.00% +2.94% -0.71% +2.16% +0.70% Change
More quotes
Financials (USD)
Sales 2018 38,5 M
EBIT 2018 -178 M
Net income 2018 -190 M
Debt 2018 197 M
Yield 2018 -
Sales 2019 8,22 M
EBIT 2019 -197 M
Net income 2019 -198 M
Debt 2019 15,9 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 19,2x
EV / Sales2019 67,9x
Capitalization 542 M
More Financials
Company
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants.Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus,... 
More about the company
Surperformance© ratings of Novavax, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVAVAX, INC.
07/05Free Technical Reports on Novavax and Three Additional Biotech Equities
AC
06/25TODAY'S RESEARCH REPORTS ON TRENDING : Novavax and Nektar Therapeutics
AC
06/15NOVAVAX INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/14NOVAVAX : New England Journal of Medicine Publishes Novavax NanoFlu Clinical Tri..
AQ
06/13NOVAVAX : New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Tr..
GL
06/13NOVAVAX : New England Journal of Medicine Publishes Novavax’ NanoFlu Clini..
AQ
05/31NOVAVAX : CEO to Discuss Future of Global Vaccine Business as Part of Panel of I..
PU
05/10NOVAVAX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
05/10NOVAVAX : 1Q Earnings Snapshot
AQ
05/09NOVAVAX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/18$PPCB 033 UNKNOWN BATTERED . 52WKH 90 cents. Won't be unknown 4 long $SHMN $L.. 
07/17$PPCB 032 UNKNOWN BATTERED . 52WKH 90 cents. Won't be unknown 4 long $SHMN $L.. 
07/17$PPCB 032 UNKNOWN BATTERED . 52WKH 90 cents. Won't be unknown 4 long $SHMN $L.. 
07/12$DRUS 0075? LOWFLOAT $1.7 MILLI CONTRACT? $SHMN $LVGI $HAON $VMGI $SIGO $CBR.. 
07/11$DRUS 0069? LOWFLOAT $1.7 MILLI CONTRACT? $SHMN $LVGI $HAON $VMGI $SIGO $CBR..
1
More tweets
Qtime:152
News from SeekingAlpha
06/14Novavax's NanoFlu vaccine improved immune responses in older adults in Phase .. 
06/10Momentum Portfolio Year-One Review - It Gained 145.19% Vs. S&P 500's 12.73% R.. 
06/08NOVAVAX : Status, Competition, Buyout Prospects 
06/06ROUNDS REPORT : Melinta Rallied While Novavax Experienced Significant Insider Pu.. 
05/30NOVAVAX : More Of The Same 
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700021040 | 4-Traders
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 3,93 $
Spread / Average Target 175%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Timothy Jon Hahn Senior VP-Global Manufacturing Operations
John J. Trizzino CFO, Treasurer, Chief Business Officer & Senior VP
Louis F. Fries Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.15.32%542
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.17%21 355
INCYTE CORPORATION-25.97%14 861
SEATTLE GENETICS, INC.31.33%11 158